{"id":"olmesartan-medoxomil-hydrochlorothiazide-if-necessary","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Dizziness"},{"rate":"3-8%","effect":"Fatigue"},{"rate":"5-15%","effect":"Hyperuricemia"},{"rate":"5-10%","effect":"Hypokalemia"},{"rate":"3-7%","effect":"Headache"},{"rate":"1-3%","effect":"Cough"},{"rate":"3-8%","effect":"Hyperglycemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Olmesartan medoxomil is an angiotensin II receptor blocker (ARB) that selectively antagonizes AT1 receptors, preventing vasoconstriction and aldosterone secretion. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing blood volume and peripheral vascular resistance. The combination provides complementary antihypertensive effects.","oneSentence":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:08.784Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension (essential hypertension)"}]},"trialDetails":[{"nctId":"NCT00751829","phase":"PHASE3","title":"Isolated Systolic Hypertension in the Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-07","conditions":"Isolated Systolic Hypertension","enrollment":417},{"nctId":"NCT00791258","phase":"PHASE4","title":"A Dose Escalation Study of a Combination Antihypertensive Drug in the Treatment of Various Groups of Patients Who do Not Respond to Single Drug Treatment of Their High Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2008-11","conditions":"Hypertension","enrollment":999},{"nctId":"NCT01101009","phase":"PHASE4","title":"Comparison of Sevikar® and the Combination of Perindopril/Amlodipine on Central Blood Pressure","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2010-04","conditions":"Hypertension","enrollment":486},{"nctId":"NCT00430638","phase":"PHASE4","title":"A Study of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Stage I and Stage II Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-12","conditions":"Hypertension","enrollment":278},{"nctId":"NCT00403481","phase":"PHASE4","title":"An Examination of the Blood Pressure Lowering Ability and Safety of Olmesartan Medoxomil in Patients With Type II Diabetes","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-11","conditions":"Hypertension","enrollment":192},{"nctId":"NCT00311155","phase":"PHASE4","title":"Olmesartan and an add-on Treatment in Patients With Mild to Moderate Hypertension","status":"COMPLETED","sponsor":"Sankyo Pharma Gmbh","startDate":"2006-03","conditions":"Essential Hypertension","enrollment":694},{"nctId":"NCT00890591","phase":"PHASE4","title":"Efficacy and Safety of Olmesartan Medoxomil in Stage 1 and 2 Essential Hypertension","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2006-08","conditions":"Essential Hypertension","enrollment":144},{"nctId":"NCT00772499","phase":"PHASE4","title":"Vascular Improvement With Olmesartan Medoxomil Study","status":"COMPLETED","sponsor":"Daiichi Sankyo","startDate":"2002-11","conditions":"Hypertension","enrollment":100},{"nctId":"NCT00751751","phase":"PHASE3","title":"Olmesartan Medoxomil Versus Losartan in Elderly and Very Elderly","status":"COMPLETED","sponsor":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","startDate":"2003-06","conditions":"Essential Hypertension","enrollment":441}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"olmesartan medoxomil + hydrochlorothiazide, if necessary","genericName":"olmesartan medoxomil + hydrochlorothiazide, if necessary","companyName":"Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company","companyId":"daiichi-sankyo-europe-gmbh-a-daiichi-sankyo-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Olmesartan medoxomil blocks angiotensin II receptors to lower blood pressure, while hydrochlorothiazide is a thiazide diuretic that reduces fluid volume and sodium reabsorption. Used for Hypertension (essential hypertension).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}